FDA/EMA Review Discord: Is Europe Slow On Oncology, Or Just Fast On Everything Else?
This article was originally published in The Pink Sheet Daily
Executive Summary
Tufts study finds that FDA approves oncology drugs in seven months and non-oncology drugs in 17 months; European Medicines Agency approval times are 27% shorter for non-oncology drugs and 54% longer for oncology therapeutics compared to FDA.
You may also be interested in...
Xtandi Gets Speedy Approval; Medivation/Astellas Already Prepped For Launch
FDA announced approval of Medivation/Astellas’ androgen receptor inhibitor Xtandi (enzalutamide) a little over three months after the NDA for metastatic castration-resistant prostate cancer was submitted, and the sponsors expect to begin promotions shortly after the U.S. Labor Day holiday.
PDUFA V Focus On Speeding FDA Drug Reviews May Be Unfounded, Study Concludes
A New England Journal of Medicine study found that FDA is faster in reviewing novel therapeutics than regulatory agencies in Europe and Canada.
Oncology Review Division At The Head Of The Pack – But Can The Others Keep Up?
Analysis of drug review performance by division finds Cardiovascular & Renal Drugs Division to occupy the lower end of the spectrum. Staffing appears to be a vital component of review performance, giving weight to the researchers’ warning of impending wholesale staff turnover.